| INTRODUCTION
The adenosine receptors are a class of four G proteincoupled receptors, A 1 , A 2A , A 2B , and A 3 , whose endogenous ligand is the purine adenosine. [1] [2] [3] The A 2A adenosine receptor (A 2A AR) is expressed in leukocytes, such as T cells, monocytes, macrophages, and natural killer cells (NKT), [2] [3] [4] and in the brain, specifically the GABAergic neurons in the basal ganglia that are responsible for voluntary movement. [4, 5] The receptor couples to the G s protein in the periphery and the G olf protein in the brain. [2, 4] The G protein stimulates the adenylyl cyclase pathway, causing a surge in cAMP, and the activation of the protein kinase A (PKA) signaling cascade. [1] [2] [3] 5] In leukocytes, the activation of PKA by the A 2A AR produces anti-inflammatory effects. [2, 3] Furthermore, a knockout of the A 2A AR in mice causes an accumulation of pro-inflammatory cytokines and leads to tissue damage. [6] When the A 2A AR is activated on T cells, the adenylyl cyclase/cAMP/PKA pathway leads to the inhibition of NF-κB, a pro-inflammatory transcription factor. [3] Additionally, the pathway activates anti-inflammatory transcription factors, which leads to the decrease in pro-inflammatory cytokines. [2] Because of its role in the immune response, A 2A AR agonists are being developed and studied for the treatment of sepsis, which is caused by hyperinflammation and characterized by multiple organ failure, and multiple sclerosis, where leukocytes attack the myelin on neurons and cause lesions in the brain. [1, 2, 7] Moreover, the anti-inflammatory role of the A 2A AR in the immune system is protective to tumors, suggesting that antagonists of the receptor can be developed to treat cancer. [8] Antagonists of the A 2A AR is a treatment option for Parkinson's disease. Parkinson's disease is a motor disorder
caused by the degradation of the dopamine pathway. In the GABAergic neurons, the activation of the A 2A AR acts counter to the D 2 dopamine signaling pathway, and suppresses dopamine release. [9] Overall, A 2A AR antagonists can treat Parkinson's disease [9] and cancer. [8] A 2A AR agonists can treat sepsis [2] and inflammation. [1, 7] Allosteric modulators bind to sites spatially different from the orthosteric binding site. [10, 11] Because allosteric regions are not as conserved as the orthosteric ones across receptor subtypes, modulators that bind to nonorthosteric sites can maintain subtype specificity. Allosteric modulators alter the association or disassociation rate of the endogenous ligand. [10] They include positive allosteric modulators (PAMs), which increase the effect of the orthosteric ligand and negative allosteric modulators (NAMs), which decrease the effect of the orthosteric ligand. [10] The structure of the A 2A AR consists of seven transmembrane helices (TM1-TM7) connected by three intracellular loops (ICL1-ICL3) and three extracellular loops (ECL1-ECL3). [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] The receptor has been crystallized in complex with agonists, including adenosine, [12] [13] [14] [15] antagonists, [16] [17] [18] [19] [20] [21] and coupled to a G protein fragment. [15] The A 2A AR has also been crystallized with interacting lipids [13, 14, 16, [19] [20] [21] and sodium ions. [20, 21] Recently, we applied molecular dynamics (MD) to the ligand-free (apo) form of two conformations of the A 2A AR X-ray structures, agonist-bound (PDB ID: 3QAK) [13] and antagonist-bound (PDB ID: 3EML). [16] We uncovered the deactivation process of the A 2A AR from the active conformation of 3QAK to the inactive crystal structure 3EML. [22] We identified four distinct conformations of the receptor, the active, intermediate 1, intermediate 2, and inactive, which were characterized particularly by the motions of the Y288 7.53 residue in the NPxxY motif. The number "288" denotes the residue number, "7" denotes the transmembrane helix number, and "53" represents the location of the residue in the transmembrane helix relative to the most conserved residue (denoted 50). [23] In the active conformation, the χ 1 angle of Y288 7.53 remained in the trans conformation and the side chain faced the intracellular region of the receptor. In the intermediate 1 conformation, Y288 7.53 interacted with residues in TM2, TM6, and TM7. In the intermediate 2 conformation, the χ 1 angle of Y288 7.53 switched from trans to gauche conformation, causing a break in the interactions between TM2 and TM6. Finally, in the simulation of the inactive A 2A AR, a salt bridge was formed between the D101 3.50 and E228 6.30 residues, or the "ionic lock". [22] In this study, we obtain representative conformations of the A 2A AR from the previous MD simulations. We identify non-orthosteric sites on the active, intermediate 1, intermediate 2, and inactive conformers, and 20 A 2A AR crystal structures using FTMap. [24] FTMap is fragment-based mapping algorithm, which screens the surface of the receptor with small probes, such as ethanol and isopropanol, and identifies hot spots based on regions of the receptor where multiple probes bind at low energy. This tool was previously used to identify five non-orthosteric sites on the β 2 -adrenergic receptor (β 2 AR), four non-orthosteric sites on the β 1 -adrenergic receptor (β 1 AR), [25] and seven non-orthosteric sites on the M 2 muscarinic receptor. [26] 
| MATERIALS AND METHODS

| Simulations
In a previous study, [22] we performed two simulations on the ligand-free A 2A AR starting from the agonist-bound (PDB ID: 3QAK) [13] and the antagonist-bound (PDB ID: 3EML) [16] X-ray structures. 3QAK was crystallized in complex with the agonist UK-432097 at a resolution of 2.71 Å. [13] 3EML was crystallized in complex with the antagonist ZM241385 at a resolution of 2.6 Å. [16] The ligands were removed from each crystal structure. In this study, the term "agonist-bound apo" denotes the ligand-free simulation starting from the 3QAK X-ray structure. The term "antagonist-bound apo" denotes the ligand-free simulation starting from the 3EML X-ray structure. The agonist-bound apo and antagonist-bound apo simulations were performed using all-atom MD simulations on the Anton supercomputer [27] for 1.57 and 1.75 μs, respectively, as previously described in Caliman et al. [22] 
| FTMap
FTMap is a fragment-based site-mapping algorithm that identifies potential binding sites on a receptor. The program docks 16 molecules, ethanol, isopropanol, isobutanol, acetone, acetaldehyde, dimethyl ether, cyclohexane, ethane, acetonitrile, urea, methylamine, phenol, benzaldehyde, benzene, acetamide, and N,N-dimethylformamide, to the surface of the receptor. [24] To use this algorithm, PDB files are uploaded to the online server, http://FTMap.bu.edu. The output of FTMap is a PDB file with the co-ordinates of the receptor and the probes found in low-energy hot spots. Hot spots are probe clusters distributed different sites of the receptor. The hot spots are identified and ranked by the FTMap protocol. [24, 28] All hot spots identified on the A 2A AR were analyzed.
| Clustering of receptor conformations
In the agonist-bound apo simulation, the receptor transitioned from the active to the intermediate 1 conformation at 250 ns. 
| Crystal structures
Twenty crystal structures were analyzed using the FTMap server. The antagonist-bound crystal structures included are shown in Table 1 , and the agonist-bound crystal structures are shown in Table 2 . The crystal structures were prepared with Schrödinger's Protein Preparation Wizard, where missing side chains, residues, and loops were added.
[29]
| Probe occupancy analysis
The total number of probes within 5 Å of the Cα atom of each residue was calculated for every receptor cluster and X-ray structure. Because these probes are small, if any atom on the probe was within 5 Å of the Cα atom a residue, it was included in the probe occupancy. The probe occupancy designates the probability that a probe was found within 5 Å of a residue. The probe occupancy was calculated by:
where P j is the number of probes within 5 Å of a residue i in receptor cluster j, N c is the total number of receptor clusters, W j is the number of simulation frames that receptor cluster j represents, N res is the total number of residues, and P is the total number of possible probes that could interact with that residue, or where 16 is the total number of probes and T is the total number of simulation frames. When the probe occupancy is calculated for all antagonist or agonist-bound crystal structures, the weight W j is 1, and T is the number of antagonist or agonist-bound crystal structures, respectively. ( Fig. S1 and Figure 1 ).
| Center-of-mass
If the distance between the center-of-mass for one hot spot was within 5 Å of the center-of-mass of another hot spot,
(1) T A B L E 1 Antagonist-bound X-ray structures used for site-mapping. The PDB ID, ligand name, and resolution, interesting features, and references are shown
they were considered a part of one larger site, and identified as a non-orthosteric site.
Figures 2-7, Fig. S3 and Figs S5-S7 were generated with VMD. [30] 3 | RESULTS AND DISCUSSION
| Probe distribution in X-ray structures
The overall distribution of probes in a receptor obtained from the FTMap analysis can help us to identify specific residues within the receptor with a propensity for interacting with drug fragments. The probe occupancy for the simulation starting agonist-bound (PDB ID: 3QAK) and simulation starting antagonist-bound (PDB ID: 3EML) X-ray structures were calculated (Fig. S1a,c) . Additionally, the probe occupancy for all antagonist-bound and all agonist-bound X-ray structures as listed in Tables 1 and 2 , respectively, was calculated ( Fig. S1b,d ).
In the simulation starting agonist-bound X-ray structure, probes interact with residues in the TM, ICL1, and ECL2 regions ( Fig. S1a) . In all agonist-bound X-ray structures, the distribution of the probes to the receptor is identical to the distribution of the simulation starting X-ray structure, but the number of residues in TM1, ICL1, TM3, ECL2, and TM6 within 5 Å of a probe increases (Fig. S1b ). In the simulation starting antagonist-bound X-ray structure, probes interact with the TM, ECL1, ECL2, and ICL2 regions of the receptor (Fig. S1c ). In the antagonist-bound X-ray structures, there are fewer residues within 5 Å of a probe in TM1, while there are more residues in the ICL1, ECL1, and TM7 regions that are within 5 Å of a probe (Fig. S1d) .
Given that there are only slight differences in the probe distribution between the X-ray structures (Fig. S1) , and that X-ray structures represent static snapshots of the receptor, an FTMap analysis on MD structures will provide a more complete description of the probe distribution, and reveal transient sites in different conformers of the receptor.
| Residues with the highest probe occupancies
In the MD sampled representative structures of the receptor, probes interact primarily with the transmembrane regions, with residues with the highest probe occupancies being found in the TM2, TM3, ECL2, TM5, and TM7 regions in the agonist-bound apo simulation (Figure 1a) , and in the TM2, TM3, TM6, and TM7 regions in the antagonist-bound apo simulation (Figure 1b) . In the X-ray structures, the residues with the highest probe occupancies are A63 , and F168 ECL2 ( Fig. S1 and Table S1 ). The residues with the highest probe occupancies in both simulations are T88 3.36 and D52 2.50 (Fig. S1, Figure 1 , Tables S1   and S2 ). Another residue with high probe occupancies in both simulations is S91 3.39 .
Residue T88 3.36 is located in the sodium ion binding site (Fig. S2 ) [31] and the orthosteric binding site in the X-ray structures of the agonist-bound A 2A AR. [12] [13] [14] The probe occupancy surrounding T88 3.36 is higher in the agonist-bound X-ray structures (0.38) compared with the antagonist-bound X-ray structures (0.03) (Table S1 ). In the agonist-bound apo simulation, the probe occupancy for T88 3.36 is 0.99, and the probe occupancy in the active conformer is 1.0 (Tables S1  and S2 ). This is consistent with previous findings that mutating T88 3.36 affects agonist binding, but not antagonist binding. [12, 13] The probe occupancy in the intermediate 1 conformer is 0.93, 0.87 in the intermediate 2 conformer, and 0.96 in the antagonist-bound apo simulation or the inactive conformer (Tables S1 and S2 ). The high probe occupancies found in the intermediate 1, intermediate 2, and inactive conformers compared to the X-ray structures are due to the entrance of a sodium ion into the sodium ion binding pocket during both simulations (Fig. S2) . The probe occupancy of D52 2.50 is 0.86 in the agonistbound apo simulation and 0.99 in the antagonist-bound apo simulation (Table S1 ). D52 2.50 is a conserved residue located [15] in the sodium ion binding site. [20, 21, 31] A sodium ion is not found in either the simulation starting agonist-bound X-ray structure [13] or the simulation starting antagonist-bound X-ray structure. [16] Appropriately, the probe occupancy surrounding D52 2.50 is 0.0 in the simulation starting agonistbound and antagonist-bound X-ray structures, as well as in most A 2A AR X-ray structures (Table S1 ). It has been suggested that sodium binding to D 2.50 triggers deactivation of the A 2A AR and other GPCRs. [20, 31, 32] In the agonist-bound apo simulation, a sodium ion enters the site at 405 ns (Fig.  S2b) , after the receptor has transitioned from the active state to intermediate 1. [22] Thus, the probe occupancy for D52 2.50 in the active conformer is 0.28 and is 1 in the intermediate 1 conformer (Table S2 ). In the antagonist-bound apo simulation, a sodium ion enters the site after 34 ns (Fig. S2c) . Residue S91 3.39 interacts with a sodium ion, [20, 31] which enters the sodium binding site in both simulations (Fig. S2) . S91 3.39 has a probe occupancy of 0.44 in the agonist-bound apo simulation and 0.42 in the antagonist-bound apo simulation, compared to 0.0 in the X-ray structures (Table S1) . Surprisingly, the probe occupancy is higher in the active con- occupancies in the agonist-bound X-ray structures compared to the antagonist-bound X-ray structures (Fig. S1b,d and Table S1 ). The TM5, ECL2, and residue S281 7.46 have higher probe occupancies in the agonist-bound apo simulation structures compared to the antagonist-bound apo simulation structures ( Figure 1a and Table S1 ). TM5 is more flexible in the agonist-bound apo simulation than in the agonist-bound apo simulation. [22] Additionally, during receptor deactivation, residue Y197 5.58 rotates the side chain toward the lipid interface, while in the antagonist-bound apo simulation, Y197 5.58 faces the helical bundle. [22] Residue S281 7.46 is also a part of the sodium ion binding pocket [20, 31] (Fig. S2 ). S281 7.46 has a probe occupancy of 0.57 in the agonist-bound apo simulation and 0.09 in the antagonist-bound apo simulation, compared to 0.0 in the starting X-ray structures (Table S1 ). The probe occupancy is 0.63 in the active and intermediate 1 conformers and 0.18 in the intermediate 2 conformer (Table S2) . TM2, TM3, A81 3.29 , and D101 3.49 have higher probe occupancies in the antagonist-bound X-ray structures than in the agonist-bound X-ray structures (Fig. S1b,d ). TM4 and TM6 (including residue W246 6.48 ), and residue L85 3.33 have higher probe occupancies in the antagonist-bound apo simulation, compared to the agonist-bound simulation. W 6.48 is located in the conserved CWxP site, a rotameric trigger for GPCR activation, [33] and residue in the sodium ion binding site (Fig.   S2a ).
[31] W246 6.48 is also a key residue identified in the intrinsic water pathway in A 2A AR. [34] During the antagonist-bound apo simulation, intracellular water molecules enter into the receptor and interact with W246 6.48 (Fig. S4b) . W246 6.48 has a probe occupancy of 0.44 in the antagonist-bound apo simulation and 0.11 in the agonist-bound apo simulation (Table  S1 ). The probe occupancy is 0.01 in the active conformer, 0.1 in the intermediate 1 conformer, and 0.14 in the intermediate 2 conformer (Table S2) . [13, 16] However, the probe occupancy in the simulation starting agonist-bound X-ray structure is much higher (0.34) than in the simulation starting antagonist-bound (0.0) X-ray structure (Table S1 ). The probe occupancy for residue L85 3.33 is 0.43 in the all agonist-bound and 0.03 in all antagonist-bound X-ray structures (Table S1 ). [22] FTMap analysis revealed sites and relevant key residues on each of these conformers (Table 3 and Figure 2 ). The inactive conformer has more non-orthosteric sites compared with the active conformer (Figure 2 ), consistent with findings on the simulation starting agonist and antagonist-bound X-ray structures (Fig. S3) . Each conformer and the X-ray structures have an orthosteric site (Figure 2 and Fig. S3) This site is smaller in the inactive conformer and the simulation starting antagonist-bound X-ray structure than in the active conformer and simulation starting agonist-bound Xray structure (Figure 2a,d and Fig. S3 ). Non-orthosteric site 1 is located in the intracellular crevice between TM3, TM4, and TM5 (Figures 2 and 3) . Nonorthosteric site 2 is located in the G protein-coupling site of TM2, TM3, TM6, and TM7 (Figures 2 and 4) . These sites are found in the active, intermediate 1, intermediate 2, and inactive conformers (Figure 2) , as well as the simulation starting agonist-bound and antagonist-bound X-ray structures (Fig.  S3) . Non-orthosteric site 3 is located on the lipid interface of TM5 and TM6 (Fig. S3 and Figure 5 ). This site is found in the intermediate 1, intermediate 2, and inactive conformers (Figure 2b-d) , and in the simulation starting antagonistbound X-ray structures (Fig. S3b) . Non-orthosteric site 4 is located on the intracellular end of TM1 and TM7, near the C-terminus (Figures 2d and 6 ). It is found in the inactive conformer (Figure 2d) , the simulation starting agonist-bound X-ray, and the simulation starting antagonist-bound X-ray structures (Fig. S3) . Non-orthosteric site 5 is located between the extracellular ends of TM3 and TM4 (Figures 2d and 7) . This site is found in the inactive conformer (Figure 2d) .
F I G U R E 1
F I G U R E 2
The key residues in each of these sites are listed in Table 3 .
| Site 1: The intracellular crevice
The "intracellular crevice" is located in between TM3, TM4, and TM5. The three regions in this site are denoted 1.1, 1.2, and 1.3 ( Figure 3 ) and correspond to the different probe clusters in the receptor. Site 1.1 is positioned closest to the intracellular region and involves residues Y112 ICL2 , D101 3.49 and A97 3.45 , and I124 4.45 (Figure 3a,b) . D 3.49 is a conserved residue of the DRY motif and Y112 ICL2 is a key residue in the G protein-coupling site. [15] This region of the intracellular crevice is located in the active, intermediate 2, and inactive conformers (Figure 2a,c,d ), and the simulation starting antagonist-bound X-ray structure (Fig. S3b) . The aromatic and hydrophobic probes that interact with this region are cyclohexane and benzene. Site 1.2 is present in every structure (Figure 2 and Fig. S3 ) and encompasses residues I92 3.40 , C185 5.46 , and ( Figure 3b,d) .
The intracellular crevice site is also found in the β 1 AR, β 2 AR, denoted sites 3 and 5 in Ref., [25] and the M 2 muscarinic receptor, denoted site 4 in Ref. [26] In the M 2 receptor, there are two components to this site, 4.1 and 4.2. Site 4.1, located closest to the intracellular region, can be found in the inactive and intermediate 2 conformers. In Ref.
, [26] 
| Site 2: G protein-coupling site
The "G protein-coupling site" is located between the intracellular ends of the TM2, TM3, TM6, and TM7 (Figure 4 ).
Allosteric modulators designed to bind to this site could prevent or enhance the binding of the G protein, attenuating the signaling cascade. In the active conformer, residues encompassing the G protein-coupling site include H230 , and the probes that interact with this site are cyclohexane, N, N-dimethylformamide, and phenol (Figure 4b ). In the inactive conformer, the interacting residues are D101 3.49 , R102
3.50 , T41 (Figure 4d ).
Probes found in this site include methylamine, acetone, cyclohexane, ethanol, urea, benzene, N, N-dimethylformamide, acetamide, and benzaldehyde. The G protein-coupling site is smaller in the active conformer and the simulation starting agonist-bound structure (Figure 2a, Fig. S3a and Figure 4a ) than in the intermediate 1, intermediate 2, and inactive conformers and simulation starting antagonist-bound Xray structure (Figure 2b-d, Fig. S3b, and Figure 4c ). In the antagonist-bound apo simulation, an internal water channel floods the intracellular region of the receptor (Fig. S4b) . In the agonist-bound apo simulation, fewer water molecules enter the receptor (Fig. S4a) .
The residues in this site are key to deactivation of the A 2A AR. [22] Residue Y288 7.53 is oriented toward the intracellular region of the receptor in the active conformation. and S234 6.36 . Next, the side chain of Y288 7.53 switches from the gauche to the trans conformation. In the inactive conformation, a salt bridge is formed between R102 3.50 and E228 6.30 .
Additionally, F242 6.44 is a residue in the sodium ion binding site. [35] R 3.50 is a key residue in the G protein-binding site. [15] This G protein-coupling site is found in the β 1 AR, β 2 AR, denoted site 4 in Ref.
, [25] and the M 2 receptor, denoted site 7 in Ref. [26] In the M 2 receptor, this site is identified only in the active state.
| Site 3: The lipid interface
The "lipid interface" site is located on the lipid exposed region of TM5 and TM6 ( Figure 5 ). It is present in the intermediate 1, intermediate 2, and inactive conformers (Figure 2b-d) , and the simulation starting antagonist-bound X-ray structure of the A 2A AR (Fig. S3b) . The residues P189 5.50 , W246 6.48 , F242
6.44 , M193 5.54 , and V239
6.41 interact with probes, such as acetone, benzene, ethane, acetaldehyde, acetamide, isobutanol, isopropanol, urea, ethanol, dimethyl ether, and acetonitrile (Figure 5b ). The conformations of P189 5.50 and F242 6.44 determine whether this site is present in the conformers ( Figure 5 and Fig. S5 ). In the active conformer, the side chains of key residues in this site, P189 5.50 and F242 6.44 , face toward each other.
The distance between the Cα atoms of these two residues is smaller than 10 Å (Fig. S5b) . When the receptor transitions to the intermediate 1 conformation in the agonist-bound apo simulation, the distance between P189 5.50 and F242 6.44 increases to an average of 12 Å (Fig. S5b) . This distances increases to 15 Å in the intermediate 2 conformer (Fig. S5b) .
In the antagonist-bound apo simulation, the distance between these two residues is consistently above 15 Å (Fig. S5c) . While this site is not present in the β 1 AR or β 2 AR receptors, [25] it is present in the inactive M 2 muscarinic receptor, denoted site 2 in Ref. [26] Allosteric modulators designed to bind to site 3 could lock the protein in the inactive or intermediate conformers, by interacting with residues P189 5.50 , F242 6 .44 , and W246 6.48 (the "toggle switch" for GPCR activation). [33] 3.8 | Site 4: The C-terminus cleft; and site
5: Extracellular cleft
The "C-terminus cleft" is located in the intracellular end of TM1 and TM7 ( Figure 6 ). It is present in the inactive conformer ( Figure 2d ) and the simulation starting antagonistbound X-ray structure (Fig. S3b) . The residues located in the C-terminus cleft include V282 7.47 , F286 7.51 , P285 7.50 , L26
1.52 , G23 1.49 , L22 1.48 , and L19 1.45 . These residues interact with benzene, cyclohexane, phenol, N, N-dimethylformamide, acetone, cyclohexane, isobutanol, and benzaldehyde (Figure 6b ). This cleft is caused by a tilt in TM1 in the inactive conformer relative to the active conformer (Fig. S6) (Fig. S6) . The "extracellular cleft" is located between the extracellular ends of TM3 and TM4 (Figure 7) . It is present in the inactive conformer (Figure 2d) (Figure 7b ). This site interacts with acetone, benzene, dimethyl ether, ethane, and phenol. The extracellular cleft is only present in the inactive conformer of the A 2A AR (Figure 2d ), but in the M 2 receptor, the extracellular cleft is found in intermediate 2 and active conformers, denoted as site 3.2 in Ref. [26] 4 | CONCLUSION The A 2A AR is a GPCR that plays a key role in the immune and neurological systems. [3, 9] In the immune system, the receptor is anti-inflammatory, and activation of the A 2A AR leads to an inhibition of pro-inflammatory cytokines and a secretion of anti-inflammatory cytokines. [2, 3, 6] In the neurological disorders, such as Parkinson's disease, A 2A AR activation acts counter to the D 2 dopamine receptor. [9] Given these roles, A 2A AR agonists are being developed for the treatment of immunological diseases, such as sepsis, and A 2A AR antagonists are being developed for the treatment of PD. [5] Allosteric modulators bind to regions outside of the orthosteric site. Some of these modulators do not have activity on their own, but either increase or decrease the activity of the endogenous ligand. [10] In this study, we applied standard FTMap, a fragment mapping technique, to analyze representative receptor structures obtained from previous agonistbound apo and antagonist-bound apo MD simulations [22] and the 20 X-ray structures of the A 2A AR to identify allosteric sites on the receptor. FTMap identified non-orthosteric sites on this membrane receptor distributed in the lipid interface, the extracellular and intracellular surfaces. Many ligands do not bind to the lipid interface of the receptor, but there are known ligands that can partition into the lipid bilayer. [36] First, we calculated the probe occupancy per residue. In the MD simulation representative clusters and the X-ray structures, probes mostly interacted with residues in the TM regions. Many residues with high probe occupancies, I92 3.40 , S281 7.46 , T88 3.36 , D52 2.50 , L85 3.33 , and W246 6.48 , are involved in sodium binding. Sodium cannot bind to the active state of the receptor. Previous A 2A AR studies have shown that a sodium ion can bind to when the receptor is in complex with an antagonist, but cannot bind when the receptor is bound to an agonist. [31] Additionally, studies of the M 3 muscarinic receptor reveal that sodium binding locks the receptor in the inactive conformation. [32] The propensity of these probes to bind to residues of the sodium ion binding site suggests that negative allosteric modulators could be developed to target this region of the receptor.
In the agonist-bound apo and antagonist-bound apo MD simulations, four key receptor conformers, active, intermediate 1, intermediate 2, and inactive, were identified during deactivation of the A 2A AR. [22] We identified five non-orthosteric sites on the A 2A AR that can be targeted for designing non-orthosteric modulators. Overall, the inactive conformer and antagonist-bound X-ray structures exhibited more non-orthosteric sites than the active conformer and agonist-bound X-ray structures. The intracellular crevice, present on all conformers, is located between the intracellular ends of TM3/TM4/TM5. This site is also present in the β 1 AR, β 2 AR, and M 2 muscarinic receptor. Key interacting residues include D101 3.49 of the conserved DRY motif. The G protein-coupling site, present on all conformers, is located in the intracellular mouth of TM2/ TM3/TM6/TM7. This site is also present in the β 1 AR, β 2 AR, and M 2 muscarinic receptor. Key interacting residues include Y288 7.53 of the NPxxY motif, and R102 3.50 of the conserved DRY motif. This site is larger in the inactive conformer than in the active conformer due the intracellular influx of water molecules. Given the role of two key residues involved in GPCR activation, Y288 7.53 and R102 3.50 of the ionic lock, either PAMs or NAMs could be developed to bind this site. The lipid interface site, present on the intermediate 1, intermediate 2, and inactive conformers, is located on the lipid interface between TM5/TM6. This site is present in the M 2 muscarinic receptor, and includes key residues including W246 6.48 . The C-terminus cleft is located in the intracellular end of TM1/ TM7. The extracellular cleft is present on the extracellular region of TM3/TM4. These sites are not found in the active conformer and thus could be targeted for designing novel NAMs.
Overall, these sites provide an array of available nonorthosteric sites on the active, intermediate 1, intermediate 2, and inactive A 2A AR conformers. These sites, including the sites found on the lipid interface, can be screened for novel PAMs for the treatment of sepsis and novel NAMs for the treatment of PD and cancer.
